Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

22 November 2021

Report highlights lack of access to antibiotics in poor countries

The Center for Infectious Disease Research and Policy (CIDRAP) reports on the launch and findings of the 2021 Antimicrobial Resistance Benchmark.

CIDRAP news reporter Chris Dall outlines the findings of the 2021 AMR Benchmark, writing: "A new analysis of how the major players in the antibiotic market are responding to the antimicrobial resistance (AMR) threat suggests that interest in antibiotic research and development is growing and that companies are making greater efforts to curb the environmental impact of antibiotic manufacturing.

"But efforts to make antibiotics more accessible to people in the countries where they are desperately needed are lagging."

Benchmark co-author and research program manager Fatema Rafiqi, who leads the AMR Benchmark team at the Access to Medicine Foundation, spoke at an online event where she launched the new Benchmark report.

"This report gives a reality check on how the biggest players in the anti-infectives market are responding to the drug resistance and access challenges we face," she is quoted as saying. "While there are bright spots of progress…the pace of change still has yet to match the scale of the AMR challenge."

Click to read the full article on the CIDRAP website.


Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved